JP2008512988A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008512988A5 JP2008512988A5 JP2007524978A JP2007524978A JP2008512988A5 JP 2008512988 A5 JP2008512988 A5 JP 2008512988A5 JP 2007524978 A JP2007524978 A JP 2007524978A JP 2007524978 A JP2007524978 A JP 2007524978A JP 2008512988 A5 JP2008512988 A5 JP 2008512988A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- rage
- immunoglobulin
- fusion protein
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (37)
- 融合タンパク質であって、イムノグロブリンのCH2ドメインまたはイムノグロブリンのCH2ドメインの部分を含むポリペプチドに直接連結されたRAGEポリペプチドを含み、ここで、該RAGEポリペプチドがRAGEリガンド結合部位を含み、さらにここで、前記融合タンパク質がイムノグロブリンFcヒンジ領域を含まない、前記融合タンパク質。
- 請求項1に記載の融合タンパク質であって、ここで、
(a)上記融合タンパク質が、前記イムノグロブリン由来のドメイン間ヒンジポリペプチドでなくRAGE由来のドメイン間リンカーを含むか;又は
(b)上記融合タンパク質が、(i)RAGEのV及びC1ドメインを分離するRAGEドメイン間リンカー、若しくは(ii)前記イムノグロブリン重鎖のヒンジ領域の代わりにRAGEのC1及びC2ドメインを分離するリンカーを含むか;又は
(c)上記融合タンパク質が、前記イムノグロブリンのFcヒンジ領域を除去し、そしてそれを前記RAGEポリペプチドで置換することによって得ることができる、
請求項1に記載の融合タンパク質。 - 前記RAGEポリペプチドが、RAGEイムノグロブリンドメインのC-末端アミノ酸がRAGEドメイン間リンカーのN-末端アミノ酸に連結され、かつ該RAGEドメイン間リンカーのC-末端アミノ酸が前記イムノグロブリンのCH2ドメイン又は前記イムノグロブリンのC H 2ドメインの部分を含むポリペプチドのN-末端アミノ酸に直接連結されるように、前記RAGEイムノグロブリンドメインに連結された前記RAGEドメイン間リンカーを含む、請求項1に記載の融合タンパク質。
- 第一のRAGEドメイン間リンカーのN-末端アミノ酸が第一のRAGEイムノグロブリンドメインのC-末端アミノ酸に連結され、第二のRAGEイムノグロブリンドメインのN-末端アミノ酸が上記第一のRAGEドメイン間リンカーのC-末端アミノ酸に連結され、第二のRAGEドメイン間リンカーのN-末端アミノ酸が上記第二のRAGEイムノグロブリンドメインのC-末端アミノ酸に連結され、そして、上記第二のRAGEドメイン間リンカーのC-末端アミノ酸が前記CH2イムノグロブリンドメインまたはイムノグロブリンのCH2ドメインの部分のN-末端アミノ酸に直接連結されるように、前記第一のRAGEイムノグロブリンドメイン及び前記第一のRAGEドメイン間リンカーに連結された、前記第二のRAGEイムノグロブリンドメイン及び第二のRAGEドメイン間リンカーを含む、請求項1〜3のいずれか1項に記載の融合タンパク質。
- 前記イムノグロブリンのCH2ドメインまたは前記イムノグロブリンのC H 2ドメインの部分に直接連結された前記第二のRAGEドメイン間リンカーが、配列番号22またはそれに対して90%同一の配列、或いは、配列番号24またはそれに対して90%同一の配列を含む、請求項4に記載の融合タンパク質。
- 前記RAGEポリペプチドが、RAGEドメイン間リンカーを介して前記CH2イムノグロブリンドメインまたは前記イムノグロブリンのCH2ドメインの部分を含むポリペプチドのN-末端アミノ酸に連結された、単一のRAGEイムノグロブリンドメインである、請求項1〜3のいずれか1項に記載の融合タンパク質。
- 前記イムノグロブリンCH2ドメイン又は前記イムノグロブリンC H 2ドメインの部分に直接連結された前記RAGEドメイン間リンカーが、配列番号21に示すアミノ酸配列またはそれに対して90%同一の配列、或いは配列番号23に示すアミノ酸配列またはそれに対して90%同一の配列を含む、請求項6に記載の融合タンパク質。
- 前記RAGEリガンド結合部位が、配列番号9に示すアミノ酸配列又はそれに対して90%同一の配列、或いは配列番号10に示すアミノ酸配列又はそれに対して90%同一の配列を含む、請求項1〜7のいずれか1項に記載の融合タンパク質。
- 前記RAGEポリペプチドが、配列番号5、配列番号6、配列番号7、配列番号8、配列番号13、配列番号14、配列番号15、配列番号16、配列番号17、配列番号18、配列番号19及び配列番号20のいずれか1つに示すアミノ酸配列を含む、請求項1に記載の融合タンパク質。
- 前記RAGEポリペプチドのアミノ酸配列が、配列番号15、配列番号16、配列番号19及び配列番号20のいずれか1つに示される、請求項1に記載の融合タンパク質。
- 前記ポリペプチドがさらに前記イムノグロブリンのC H 3ドメイン又はその部分を含む、請求項1〜10のいずれか1項に記載の融合タンパク質。
- 前記イムノグロブリンのC H 2ドメイン又は前記イムノグロブリンのC H 2ドメインの部分を含む前記ポリペプチドのアミノ酸配列が、配列番号38に示すアミノ酸配列であるか、又はそれを含む、請求項11に記載の融合タンパク質。
- 前記イムノグロブリンが、IgA、IgD、IgE、IgG及びIgMから成る群から選ばれるヒトイムノグロブリンである、請求項1〜11のいずれか1項に記載の融合タンパク質。
- 前記イムノグロブリンが、IgA1、IgA2、IgG1、IgG2、IgG3及びIgG4からなる群から選ばれる、請求項13に記載の融合タンパク質。
- 前記イムノグロブリンがIgG1である。請求項14に記載の融合タンパク質。
- 以下の:配列番号32、配列番号33、配列番号34、配列番号35、配列番号36、及び配列番号37のいずれか1つに示すアミノ酸配列を含む、融合タンパク質。
- 配列番号37又は配列番号34に示すアミノ酸配列を有する融合タンパク質。
- 配列番号30又は配列番号31に示す核酸配列によりコードされる、融合タンパク質。
- 請求項1〜18のいずれか1項に記載の融合タンパク質をコードする核酸。
- 前記RAGEポリペプチドをコードする核酸配列が、配列番号25、配列番号26、配列番号27、配列番号28及び配列番号29のいずれか1つに示す核酸配列であるか、又はそれを含む、請求項19に記載の核酸。
- 配列番号30または配列番号31に示す核酸配列を含む、請求項20に記載の核酸。
- 請求項1〜18のいずれか1項に記載の融合タンパク質をコードし、及び/又は請求項19〜21のいずれか1項に記載の核酸を含む、発現ベクター。
- 医薬担体中の治療的有効量の請求項1〜18のいずれか1項に記載の融合タンパク質を含む医薬組成物。
- 注射用溶液又は滅菌された凍結乾燥粉末として製剤される、請求項23に記載の医薬組成物。
- 請求項1〜18いずれか1項に記載の融合タンパク質の製造方法であって、前記RAGEポリペプチドを、前記イムノグロブリンのCH2ドメインまたは前記イムノグロブリンのCH2ドメインの部分を含む前記ポリペプチドに共有結合させるステップを含む、前記方法。
- 前記融合タンパク質が組換えDNA構築物によってコードされる、請求項25に記載の方法。
- さらに、前記DNA構築物を発現ベクター中に組み込むステップを含む、請求項25又は26に記載の方法。
- 前記発現ベクターを宿主細胞中にトランスフェクトすることを含む、請求項27に記載の方法。
- 対象におけるRAGE介在性の障害を治療するための医薬の製造における、請求項1〜18のいずれか1項に記載の融合タンパク質の使用。
- 前記RAGE融合タンパク質の前記対象への静脈内投与、腹腔内投与又は皮下投与を目的とする、請求項29に記載の使用。
- 前記医薬が、糖尿病の症状または糖尿病の後期合併症の症状を治療することを目的とする、請求項29又は30に記載の使用。
- 前記糖尿病または糖尿病の後期合併症の症状が、糖尿病性腎症、糖尿病性網膜症、糖尿病性の脚の潰瘍、循環器の合併症又は糖尿病性ニューロパチーを含む、請求項31に記載の使用。
- 前記医薬が、アミロイドーシス、アルツハイマー病、癌、腎障害、または、自己免疫、炎症性腸疾患、リューマチ関節炎、乾癬、多発性硬化症、低酸素症、脳卒中、心臓発作、出血性ショック、敗血症、器官移植、若しくは創傷治癒の障害に関連する炎症を治療することを目的とする、請求項29又は30に記載の方法。
- 請求項22に記載の発現ベクターを含む宿主細胞。
- チャイニーズハムスター卵母細胞である。請求項34に記載の宿主細胞。
- 請求項34又は35に記載の宿主細胞を培養することを含む、融合タンパク質の製造方法。
- 請求項36に記載の方法により製造された融合タンパク質。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59855504P | 2004-08-03 | 2004-08-03 | |
US60/598,555 | 2004-08-03 | ||
PCT/US2005/027705 WO2006017647A1 (en) | 2004-08-03 | 2005-08-03 | Rage fusion proteins and methods of use |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008512988A JP2008512988A (ja) | 2008-05-01 |
JP2008512988A5 true JP2008512988A5 (ja) | 2009-06-04 |
JP5188804B2 JP5188804B2 (ja) | 2013-04-24 |
Family
ID=35149359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007524978A Expired - Fee Related JP5188804B2 (ja) | 2004-08-03 | 2005-08-03 | Rage融合タンパク質及びその使用方法 |
Country Status (23)
Country | Link |
---|---|
US (5) | US7981423B2 (ja) |
EP (1) | EP1781700B1 (ja) |
JP (1) | JP5188804B2 (ja) |
KR (1) | KR101323411B1 (ja) |
CN (1) | CN1993378A (ja) |
AP (1) | AP2007003869A0 (ja) |
AU (1) | AU2005271452B2 (ja) |
BR (1) | BRPI0514052A (ja) |
CA (1) | CA2570324C (ja) |
CR (1) | CR20110556A (ja) |
EA (1) | EA012082B1 (ja) |
EC (1) | ECSP077221A (ja) |
ES (1) | ES2473587T3 (ja) |
GE (1) | GEP20105110B (ja) |
IL (1) | IL180554A (ja) |
MA (1) | MA29067B1 (ja) |
MX (1) | MX2007001559A (ja) |
NO (1) | NO20065949L (ja) |
NZ (1) | NZ552128A (ja) |
TN (1) | TNSN07037A1 (ja) |
UA (1) | UA93356C2 (ja) |
WO (1) | WO2006017647A1 (ja) |
ZA (2) | ZA200700643B (ja) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6465422B1 (en) * | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
US7696169B2 (en) * | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
WO2005026209A2 (en) * | 2003-09-11 | 2005-03-24 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
UA92154C2 (ru) * | 2004-08-03 | 2010-10-11 | Транстек Фарма, Инк. | Rage-слитые белки и способы их применения |
UA93356C2 (ru) * | 2004-08-03 | 2011-02-10 | Tpahctek Фарма, Инк. | Белки слияния ha ochobe rage и способы их использования |
US7964706B2 (en) * | 2004-10-22 | 2011-06-21 | Medimmune, Llc | High affinity antibodies against HMGB1 and methods of use thereof |
WO2006119510A2 (en) * | 2005-05-04 | 2006-11-09 | Receptor Biologix, Inc. | Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same |
CA2634908C (en) * | 2005-12-23 | 2015-05-19 | Gcoder Systems Ab | Positioning pattern |
US20090004190A1 (en) * | 2006-02-09 | 2009-01-01 | Mjalli Adnan M M | Rage Fusion Proteins And Methods Of Use |
EP2021474A2 (en) * | 2006-05-05 | 2009-02-11 | Transtech Pharma, Inc. | Rage fusion proteins, formulations, and methods of use thereof |
CN103755789B (zh) | 2007-01-30 | 2016-12-07 | 埃皮瓦克斯公司 | 调节性t细胞表位、组合物及其用途 |
US20080199467A1 (en) * | 2007-02-15 | 2008-08-21 | Mjalli Adnan M M | Immunoglobulin fusion proteins and methods of making |
US20100254983A1 (en) * | 2007-06-07 | 2010-10-07 | Ann Marie Schmidt | Uses of rage antagonists for treating obesity and related diseases |
CN101842382A (zh) | 2007-06-14 | 2010-09-22 | 卡拉狄加制药公司 | Rage融合蛋白 |
EP2230300A4 (en) * | 2007-10-24 | 2012-08-08 | Otsuka Chemical Holdings Co Ltd | POLYPEPTIDE WITH IMPROVED EFFECTOR FUNCTION |
NL2001552C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001555C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001553C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001558C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001551C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001556C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001554C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001557C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
EP2789684B1 (en) | 2008-05-23 | 2016-12-21 | Siwa Corporation | Methods and compositions for facilitating regeneration |
WO2010122460A1 (en) | 2009-04-20 | 2010-10-28 | Pfizer Inc. | Control of protein glycosylation and compositions and methods relating thereto |
US10080799B2 (en) | 2010-02-12 | 2018-09-25 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions related to glycoprotein-immunoglobulin fusions |
WO2011102845A1 (en) * | 2010-02-18 | 2011-08-25 | Transtech Pharma, Inc. | Rage fusion protein compositions and methods of use |
WO2012047629A2 (en) | 2010-09-27 | 2012-04-12 | Siwa Corporation | Selective removal of age-modified cells for treatment of ather0sclerosis |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
ES2746052T3 (es) | 2011-06-28 | 2020-03-04 | Inhibrx Lp | Polipéptidos de fusión de serpina y métodos de uso de los mismos |
CA2839622A1 (en) * | 2011-06-28 | 2013-01-03 | Inhibrx Llc | Wap domain fusion polypeptides and methods of use thereof |
US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
SG11201500682WA (en) * | 2012-09-07 | 2015-02-27 | Sanofi Sa | Fusion proteins for treating a metabolic syndrome |
WO2015023165A1 (ko) * | 2013-08-16 | 2015-02-19 | 가톨릭대학교 산학협력단 | 염증조절복합체 및 stat3 신호분자 차단을 통한 면역조절능 최적화된 안정화 중간엽줄기세포 |
IL251210B2 (en) * | 2014-09-19 | 2023-12-01 | Siwa Corp | Anti-aging antibodies for the treatment of inflammation and autoimmune disorders |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
CN109071675A (zh) | 2016-02-19 | 2018-12-21 | Siwa有限公司 | 使用高级糖化终产物(age)的抗体治疗癌症、杀死转移性癌细胞和预防癌症转移的方法和组合物 |
WO2018191718A1 (en) | 2017-04-13 | 2018-10-18 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
US11958900B2 (en) | 2016-04-15 | 2024-04-16 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
US20190263918A1 (en) * | 2016-06-08 | 2019-08-29 | Shanghai Jiao Tong University School Of Medicine | Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity |
WO2017222535A1 (en) | 2016-06-23 | 2017-12-28 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
US10143187B2 (en) | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
EP3583119A2 (en) * | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc. | Engineered polypeptides |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
JP7307178B2 (ja) | 2018-09-14 | 2023-07-11 | バイオエイジ ラブス, インコーポレイテッド | 改善された安定性およびリガンド結合親和性を有するrage融合タンパク質ならびにその使用 |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
NZ235148A (en) | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
SE9201073D0 (sv) | 1992-04-03 | 1992-04-03 | Kabi Pharmacia Ab | Protein formulation |
ES2198414T3 (es) | 1992-10-23 | 2004-02-01 | Immunex Corporation | Procedimientos para preparar proteinas oligomericas solubles. |
MX9705449A (es) | 1995-01-18 | 1998-02-28 | Alteon Inc | Uso de compuestos de tiazolio para evitar y revertir la formacion de productos finales de glicosilacion avanzada. |
FI119756B (fi) | 1995-01-18 | 2009-03-13 | Alteon Inc | Tiatsoliumyhdisteiden käyttö pitkälle edenneen glykosylaation lopputuotteiden muodostumisen estossa ja suunnan muutoksessa |
US5656261A (en) | 1995-01-18 | 1997-08-12 | The Picower Institute For Medical Research | Preventing and reversing advanced glycosylation endproducts |
EP0827511A1 (en) | 1995-04-05 | 1998-03-11 | The Picower Institute For Medical Research | Agents for binding to advanced glycosylation endproducts, and methods of their use |
US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
AU1832797A (en) | 1996-01-26 | 1997-08-20 | Trustees Of Columbia University In The City Of New York, The | A polypeptide from lung extract which binds amyloid-beta peptide |
WO1997039121A1 (en) | 1996-04-16 | 1997-10-23 | Schering Aktiengesellschaft | Advanced glycosylation end-product receptor peptides and uses therefor |
US5864018A (en) | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
US7081241B1 (en) | 1998-10-06 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Extracellular rage binding protein (EN-RAGE) and uses thereof |
US6790443B2 (en) | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
US7258857B2 (en) | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
US6555651B2 (en) | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
CA2284170C (en) | 1997-03-11 | 2008-12-02 | The General Hospital Corporation | Identification of agents for use in the treatment of alzheimer's disease |
US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
US7101838B2 (en) | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
MY131805A (en) | 1997-09-18 | 2007-09-28 | Biogen Idec Inc | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis. |
US6380165B1 (en) | 1997-09-19 | 2002-04-30 | The Picower Institute For Medical Research | Immunological advanced glycation endproduct crosslink |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6323218B1 (en) | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
US6465422B1 (en) | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
WO2000018970A1 (fr) | 1998-09-29 | 2000-04-06 | Asahi Kasei Kabushiki Kaisha | Procede de commande de liberation de granules |
US6753150B2 (en) | 1998-10-05 | 2004-06-22 | The Trustees Of Columbia University In The City Of New York | Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
AU765719B2 (en) | 1998-10-06 | 2003-09-25 | Trustees Of Columbia University In The City Of New York, The | Extracellular novel rage binding protein (EN-RAGE) and uses thereof |
US6197294B1 (en) | 1998-10-26 | 2001-03-06 | Neurotech S.A. | Cell surface molecule-induced macrophage activation |
US6605642B2 (en) | 1999-04-05 | 2003-08-12 | City Of Hope | Inhibitors of formation of advanced glycation endproducts (AGES) |
US6589944B1 (en) | 1999-04-05 | 2003-07-08 | City Of Hope | Breakers of advanced glycation endproducts |
US6787566B2 (en) | 1999-04-05 | 2004-09-07 | City Of Hope | Breakers of advanced glycation endproducts |
US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
US6835200B2 (en) | 1999-06-22 | 2004-12-28 | Ndo Surgical. Inc. | Method and devices for tissue reconfiguration |
FR2797402B1 (fr) | 1999-07-15 | 2004-03-12 | Biomerieux Stelhys | Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune |
AU6766800A (en) | 1999-08-13 | 2001-03-13 | Trustees Of Columbia University In The City Of New York, The | Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof |
EP1219639A4 (en) | 1999-09-08 | 2009-03-25 | Toray Industries | CIPO - Patent |
US20050170382A1 (en) | 1999-10-06 | 2005-08-04 | The Trustees Of Columbia University In The City Of New York. | RAGE-related compositions |
EP2319939A3 (en) | 1999-10-21 | 2012-09-26 | Case Western Reserve University | Gene expression profiling of inflammatory bowel disease |
WO2001042451A2 (en) | 1999-12-08 | 2001-06-14 | Genset | FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS |
AU5355501A (en) | 2000-04-14 | 2001-10-30 | Niadyne Corp | Method for identifying regulators of protein-advanced glycation end product (protein-age) formation |
US6727353B2 (en) * | 2000-04-14 | 2004-04-27 | Icagen, Inc. | Nucleic acid encoding Kv10.1, a voltage-gated potassium channel from human brain |
EP1354037A2 (en) | 2000-04-17 | 2003-10-22 | TransTech Pharma, Inc. | Protein expression system arrays and use in biological screening |
EP1358348A2 (en) | 2000-05-09 | 2003-11-05 | Genetics Institute, LLC | Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis |
US6908741B1 (en) | 2000-05-30 | 2005-06-21 | Transtech Pharma, Inc. | Methods to identify compounds that modulate RAGE |
US20050026811A1 (en) | 2003-05-20 | 2005-02-03 | Mjalli Adnan M. M. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
US6613801B2 (en) | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
WO2002013262A2 (en) * | 2000-08-07 | 2002-02-14 | Amberwave Systems Corporation | Gate technology for strained surface channel and strained buried channel mosfet devices |
US6825164B1 (en) | 2000-08-14 | 2004-11-30 | The Trustees Of Columbia University In The City Of New York | Method to increase cerebral blood flow in amyloid angiopathy |
US6563015B1 (en) | 2000-08-14 | 2003-05-13 | The Trustees Of Columbia University In The City Of New York | Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof |
BR0114411A (pt) | 2000-10-02 | 2006-05-09 | Reddy Us Therapeutics Inc | métodos e composições para o tratamento de doenças inflamatórias |
AU2002213192A1 (en) | 2000-10-13 | 2002-04-22 | The Trustees Of Columbia University In The City Of New York | A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury |
US20050244849A1 (en) | 2000-12-15 | 2005-11-03 | Genetics Institute, Llc | Screening assays for rheumatoid arthritis |
EP1368648A2 (en) | 2000-12-29 | 2003-12-10 | Reddy US Therapeutics, Inc. | Detection of compounds that modulate inflammatory responses |
US6946277B2 (en) | 2001-01-31 | 2005-09-20 | Council Of Scientific And Industrial Research | Method for enhancing cellobiase activity of termitomyces clypeatus using a glycosylation inhibitor |
EP1361891A2 (en) | 2001-02-19 | 2003-11-19 | MERCK PATENT GmbH | Artificial fusion proteins with reduced immunogenicity |
DE10109466B4 (de) | 2001-02-28 | 2008-01-10 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren und Mittel zur Modifikation humaner Angiogenese |
JP3837494B2 (ja) | 2001-03-19 | 2006-10-25 | 国立大学法人金沢大学 | 可溶型rageタンパク質 |
EP1370571B1 (en) * | 2001-03-22 | 2005-06-15 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Methods and apparatus for gel-free qualitative and quantitative proteome analysis, and uses therefor |
US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
EP1578434A2 (en) | 2002-07-09 | 2005-09-28 | Point Therapeutics, Inc. | Methods and compositions relating to isoleucine boroproline compounds |
CN1774445A (zh) * | 2002-08-16 | 2006-05-17 | 惠氏公司 | 用于治疗rage相关病症的组合物和方法 |
US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
AU2003285385A1 (en) | 2002-12-13 | 2004-07-09 | Licentia Ltd | The transmembrane protein amigo and uses thereof |
MXPA05010773A (es) | 2003-04-09 | 2005-12-12 | Neose Technologies Inc | Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos. |
US8067371B2 (en) | 2003-05-09 | 2011-11-29 | The Trustees Of Columbia University In The City Of New York | RAGE G82S-related methods and compositions for treating inflammatory disorders |
WO2005021710A2 (en) | 2003-06-02 | 2005-03-10 | University Of Miami | Chimeric molecules and methods of use |
WO2005019429A2 (en) | 2003-08-22 | 2005-03-03 | Potentia Pharmaceuticals, Inc. | Compositions and methods for enhancing phagocytosis or phagocyte activity |
EP1660014A4 (en) | 2003-09-05 | 2009-07-22 | Univ Columbia | METHODS AND COMPOSITIONS ASSOCIATED WITH THE TERMINAL PRODUCTS OF ADVANCED GLYCATION FOR THE TREATMENT OF GLOMERULAR LESION |
WO2005042032A1 (en) | 2003-10-31 | 2005-05-12 | The Trustees Of Columbia University In The City Of New York | Methods for treating multiple sclerosis |
WO2005049852A2 (en) | 2003-11-17 | 2005-06-02 | University Of Florida | Methods and compositions for inducing apoptosis |
WO2005051995A2 (en) | 2003-11-19 | 2005-06-09 | Curagen Corporation | Novel advanced glycosylation end product-specific receptor-like protein and nucleic acids encoding same |
GB0330079D0 (en) | 2003-12-20 | 2004-02-04 | Bioinvent Int Ab | Vaccine |
CN100342017C (zh) | 2004-05-10 | 2007-10-10 | 中国医学科学院肿瘤医院肿瘤研究所 | 基因重组趋化抗原疫苗 |
ATE399014T1 (de) | 2004-07-02 | 2008-07-15 | Creabilis Therapeutics Spa | Nukleinsäuren zur behandlung von erkrankungen im zusammenhang mit hmgb1 |
US20060012414A1 (en) * | 2004-07-15 | 2006-01-19 | Texas Instruments Incorporated | Circuit and method for generating a polyphase clock signal and system incorporating the same |
WO2006012373A2 (en) | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
US7470521B2 (en) | 2004-07-20 | 2008-12-30 | Critical Therapeutics, Inc. | RAGE protein derivatives |
UA93356C2 (ru) | 2004-08-03 | 2011-02-10 | Tpahctek Фарма, Инк. | Белки слияния ha ochobe rage и способы их использования |
UA92154C2 (ru) | 2004-08-03 | 2010-10-11 | Транстек Фарма, Инк. | Rage-слитые белки и способы их применения |
WO2006036922A2 (en) | 2004-09-27 | 2006-04-06 | Centocor, Inc. | Srage mimetibody, compositions, methods and uses |
WO2006119510A2 (en) | 2005-05-04 | 2006-11-09 | Receptor Biologix, Inc. | Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same |
US20080207499A1 (en) | 2005-06-29 | 2008-08-28 | Gaetano Barile | Rage-related methods for treating and preventing diabetic retinopathy |
US20090004190A1 (en) | 2006-02-09 | 2009-01-01 | Mjalli Adnan M M | Rage Fusion Proteins And Methods Of Use |
EP2021474A2 (en) | 2006-05-05 | 2009-02-11 | Transtech Pharma, Inc. | Rage fusion proteins, formulations, and methods of use thereof |
ES2541546T3 (es) | 2006-11-03 | 2015-07-21 | Wyeth Llc | Sustancias que inhiben la glucólisis en cultivo celular |
US20080199467A1 (en) | 2007-02-15 | 2008-08-21 | Mjalli Adnan M M | Immunoglobulin fusion proteins and methods of making |
CN101842382A (zh) | 2007-06-14 | 2010-09-22 | 卡拉狄加制药公司 | Rage融合蛋白 |
-
2005
- 2005-08-03 UA UAA200702273A patent/UA93356C2/ru unknown
- 2005-08-03 AP AP2007003869A patent/AP2007003869A0/xx unknown
- 2005-08-03 US US11/629,437 patent/US7981423B2/en not_active Expired - Fee Related
- 2005-08-03 KR KR1020077005152A patent/KR101323411B1/ko not_active IP Right Cessation
- 2005-08-03 CA CA2570324A patent/CA2570324C/en not_active Expired - Fee Related
- 2005-08-03 NZ NZ552128A patent/NZ552128A/en not_active IP Right Cessation
- 2005-08-03 EP EP05778764.0A patent/EP1781700B1/en active Active
- 2005-08-03 ES ES05778764.0T patent/ES2473587T3/es active Active
- 2005-08-03 US US11/197,038 patent/US7901688B2/en not_active Expired - Fee Related
- 2005-08-03 MX MX2007001559A patent/MX2007001559A/es active IP Right Grant
- 2005-08-03 WO PCT/US2005/027705 patent/WO2006017647A1/en active Application Filing
- 2005-08-03 GE GEAP20059904A patent/GEP20105110B/en unknown
- 2005-08-03 AU AU2005271452A patent/AU2005271452B2/en not_active Ceased
- 2005-08-03 BR BRPI0514052-8A patent/BRPI0514052A/pt not_active IP Right Cessation
- 2005-08-03 EA EA200700404A patent/EA012082B1/ru not_active IP Right Cessation
- 2005-08-03 JP JP2007524978A patent/JP5188804B2/ja not_active Expired - Fee Related
- 2005-08-03 CN CNA2005800259477A patent/CN1993378A/zh active Pending
-
2006
- 2006-12-21 NO NO20065949A patent/NO20065949L/no not_active Application Discontinuation
-
2007
- 2007-01-04 IL IL180554A patent/IL180554A/en not_active IP Right Cessation
- 2007-01-23 ZA ZA200700643A patent/ZA200700643B/xx unknown
- 2007-02-02 EC EC2007007221A patent/ECSP077221A/es unknown
- 2007-02-02 MA MA29650A patent/MA29067B1/fr unknown
- 2007-02-02 TN TNP2007000037A patent/TNSN07037A1/fr unknown
-
2009
- 2009-09-16 ZA ZA200906459A patent/ZA200906459B/xx unknown
-
2011
- 2011-01-03 US US12/983,604 patent/US8877192B2/en not_active Expired - Fee Related
- 2011-01-07 US US12/986,602 patent/US20110124102A1/en not_active Abandoned
- 2011-02-17 US US13/029,622 patent/US20110244516A1/en not_active Abandoned
- 2011-10-20 CR CR20110556A patent/CR20110556A/es not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008512988A5 (ja) | ||
US8193322B2 (en) | Methods for generating monovalent IgG | |
US10214579B2 (en) | Fc fusion proteins comprising novel linkers or arrangements | |
US20180044437A1 (en) | Anti-inflammatory molecules with tissue-targeting functions | |
JP2008508882A5 (ja) | ||
RU2007119989A (ru) | Композиции, слитые конструкции и конъюгаты plad домена | |
CN106279437B (zh) | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 | |
JP2020500885A5 (ja) | ||
JP2009523459A5 (ja) | ||
JP2011506476A5 (ja) | ||
TW201706312A (zh) | 用以治療疾病的分子構建體 | |
JP2010532764A5 (ja) | ||
TW201336865A (zh) | 免疫球蛋白Fc變體 | |
CN103917563A (zh) | 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法 | |
TWI691512B (zh) | Fc融合高親和性IgE受體α鏈 | |
CN103897057B (zh) | 多价抗体片段与其三聚复合物 | |
JP2018503355A5 (ja) | ||
EP4303231A1 (en) | Bispecific antibody | |
KR20140135766A (ko) | 종양괴사인자 수용체 융합 단백질 및 이를 이용하는 방법 | |
JP2005522192A5 (ja) | ||
US7557084B2 (en) | IL-18 specific polypeptides and therapeutic uses thereof | |
CN109796534B (zh) | 抗il-17抗体/tnfr ecd融合蛋白及其用途 | |
Liu et al. | Targeting TNF-α with a tetravalent mini-antibody TNF-TeAb | |
JPWO2020018503A5 (ja) | ||
JPWO2019121906A5 (ja) | Pd-li抗原結合部位を有するfc結合断片 |